Business Wire

CMR Surgical: Galaxy Care Becomes First Hospital in the World to Acquire the Versius Surgical Robotic System

Share

CMR Surgical Ltd today announced that Galaxy Care Hospital in Pune, India, has become the first hospital in the world to procure Versius ® , a next-generation surgical robotic system. A range of surgical procedures have already been conducted using Versius® at the world-renowned centre for laparoscopy, including transthoracic, hysterectomies and myomectomies, under the leadership of Dr. Shailesh Puntambekar.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191015005940/en/

Galaxy Care is a well-established centre of excellence for laparoscopic surgery and the introduction of Versius ® will support the hospital to bring robotic-assisted laparoscopic surgery to more people. Dr Shailesh Puntambekar, Consultant Oncologist, Surgeon and Medical Director of Galaxy Care will lead the team using Versius ® . He is an international pioneer in surgery and renowned for his advanced laparoscopic skills. In addition to this, he is responsible for training laparoscopy to surgeons from all over the world, helping to bring the benefits of minimal access surgery to patients globally.

Dr Puntambekar has led the way in bringing surgical robotics to India, having performed robotic-assisted surgery in India for over a decade and will be responsible for the introduction of Versius ® to Galaxy Care. Versius ® as a next-generation surgical robotic system with its small form factor, versatility and portability has been designed to support surgeons to deliver the benefits of minimal access surgery to patients around the world.

“As an experienced surgeon in robotic assisted surgery I think that there is significant potential for Versius ® to further increase access to laparoscopic surgery for my patients, so it was a natural choice to acquire this system. Versius ® , as a small and cost-effective system is well suited for meeting the high surgical demand in India. We are excited to bring the next-generation surgical robot to India.” said Dr. Shailesh Puntambekar, Medical Director at Galaxy Care Hospital, Pune, India.

“Galaxy Care has become our first customer to acquire and use Versius ® and this is an important milestone in bringing the benefits of minimal access surgery to all. We are pleased to be working with a centre that has some of the best surgeons in the world, meeting a high surgical demand. It is important that we bring Versius ® to market responsibly and we are delighted to be working closely with Galaxy Care on the introduction of Versius ® in the hospital”, said Mark Slack, Chief Medical Officer, CMR Surgical.

The commercial introduction of Versius ® also marks the launch of the world’s first clinical registry for a surgical robotic system. The registry is part of CMR Surgical’s commitment to post-market surveillance as part of the IDEAL framework and a responsible introduction of a medical device. The clinical registry managed by CMR Surgical, working in partnership with customers is recording and monitoring the patient outcomes of all procedures conducted using the Versius ® Surgical Robotic System in order to ensure patient safety. Outcome measures being recorded include: operative time, length of stay, return to hospital within 30 days, and return to operating room within 24 hours.

In addition to the first global commercial deal taking place in India, the Versius® Surgical Robotic System is expected to be introduced in hospitals across Europe later in 2019.

---ENDS---

About the Galaxy Care Hospital, Pune, India

Galaxy Care Hospital located in Pune, India is a specialist centre in laparoscopic and Robotic cancer surgeries. It has the first and only robotic theatre in western and southern India. The hospital is led by Medical Director Dr. Shailesh Puntambekar who has performed a number of internationally acclaimed procedures including India’s first successful womb transplant as well as pioneering laparoscopic radical hysterectomy for early stage cervical cancer, known globally as the Pune technique. Galaxy Care is now associated with the Care Group of Hospitals, with a number of hospitals across India.

About the Clinical Registry

The clinical registry established by CMR Surgical, working in partnership with customers will support post-market surveillance for the Versius ® Surgical Robotic System. The clinical registry will be collecting the following clinical data on procedures conducted using Versius ® : patient demographics, surgical history, date of diagnosis, planned procedure, operative time, estimated blood loss, return to operating theatre within 24 hours, length of stay, return to hospital within 30 days, mortality at 90 days, any complications that may have occurred. All data is anonymised.

About the Versius® Surgical Robotic System

Versius® resets expectations of robotic surgery by providing a versatile system that is portable, transportable and affordable. This is made possible because of its elegant form factor, modular design and individually cart-mounted arms. Versius® can move between operating rooms and even hospitals/clinics and gives the surgical team excellent access to the patient at all times.

Biomimicking the human arm, Versius® allows surgeons the freedom of port placement, but with the benefits of small fully-wristed instruments. With 3D HD vision, easy-to adopt instrument control and a choice of ergonomic working positions, the new open surgeon console has the potential to reduce stress and fatigue and extend the careers of surgeons.

About CMR Surgical Limited

CMR Surgical is a British private limited company developing the next-generation universal robotic system, Versius®, for minimal access surgery. The company received the European CE Mark in March 2019 for the Versius® Surgical Robotic System.

The vision behind CMR Surgical is to make minimal access surgery universally accessible and affordable, transforming the existing market for surgical robotics while also addressing the six million people who still undergo open surgery each year.

Global annual revenues for robot-assisted minimal access surgery are presently approximately $4 billion and are anticipated to reach $20 billion by 2025.

CMR Surgical, formed in 2014, has its headquarters in Cambridge, United Kingdom and is backed by an international shareholder base of specialist and generalist investors.

The Company achieved the registration of its Quality Management System to ISO 13485:2016 by Underwriters Laboratories LLC® (UL), and the status as a UL Registered Firm, in September 2015.

For further information, please visit www.cmrsurgical.com

Contact information

CMR Surgical
Patrick Pordage/ Sarah Ghabina
patrick.pordage@cmrsurgical.com/ sarah.ghabina@cmrsurgical.com
+44 (0)7864 922341 /+44 (0)7749 432373

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

A Better Alternative to Banking - ClubSwan.com27.1.2020 12:00:00 EETPress release

ClubSwan.com, the leader in membership driven financial solutions, further expands its innovative alternative banking capabilities to key global markets. As traditional financial institutions continually struggle to provide innovative and meaningful ways to bring value to individual and corporate customers and as digital assets/crypto currencies are experiencing global growth, ClubSwan.com continues to evolve to meet the efficiencies and demands that these new assets and our customers require and to which traditional banks have no answer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200127005046/en/ Instead, closed bank accounts, rejected transactions, crippling delays with customers receiving their funds (if at all) are all the norm with traditional banks. To add to this dilemma, the availability of trustworthy solutions where customers have peace of mind for both crypto assets and traditional currencies have been non-exi

GSMA Recognizes Turkcell and P.I. Works for the Value of AI Based Network Automation27.1.2020 10:00:00 EETPress release

Turkcell and P.I. Works have been recognized by GSMA Future Networks Programme for achieving exceptional efficiency gains in network operations and ensuring superior customer experience. P.I. Works and Turkcell have successfully shown that the AI based, service aware network automation delivered stronger improvements as compared to conventional automation solutions. The details of the deployed solutions and their benefits are provided in a joint white paper authored by GSMA, Turkcell and P.I. Works under GSMA’s Future Networks Programme. To read the white paper please visit: https://www.gsma.com/futurenetworks/wiki/case-study-ai-use-cases-in-service-assurance/ GSMA Future Networks Programme intends to help operators share best practices and discover new opportunities that will enable them to reduce operational and capital expenditures. Given the success of the project, GSMA invited Turkcell and P.I. Works to join the program and provide insights for the AI-based, Service Aware Automate

Phase 2 DESTINY-Gastric01 Trial of DS-8201 Versus Chemotherapy Met Primary Endpoint27.1.2020 10:00:00 EETPress release

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca today announced positive topline results from the pivotal phase 2 DESTINY-Gastric01 trial of DS-8201, a HER2 directed antibody drug conjugate (ADC), in patients with HER2 positive unresectable or metastatic gastric or gastroesophageal junction cancer that had progressed following two or more treatment regimens including trastuzumab and chemotherapy. The trial met its primary endpoint, achieving a statistically significant and clinically meaningful improvement in objective response rate (ORR), as assessed by an independent review committee, in patients treated with DS-8201 versus investigator’s choice of chemotherapy (irinotecan or paclitaxel monotherapy). DS-8201 also showed a statistically significant and clinically meaningful improvement in overall survival (OS), a key secondary endpoint. The safety profile observed for DS-8201 in DESTINY-Gastric01 was consistent with previous clinical trials. These results c

HighRes Biosolutions and Novo Nordisk partner to transform drug discovery in automated Lab of the Future24.1.2020 17:00:00 EETPress release

HighRes Biosolutions and Novo Nordisk A/S today announced that they will collaborate to design a state-of-the-art robotic platform for high-throughput biologics engineering and characterisation. The integration of a multi-system robotics platform with sophisticated software control architecture will enable a digital transformation and accelerated discovery for Novo Nordisk’s peptide and large molecule therapeutics research. “In order to maintain our leadership within biologics engineering we are investing in a fully automated and digital design platform. This investment is linked to our build-up in AI and advanced analytics and demonstrates Novo Nordisk’s commitment as a world leading biologics research company,” said Lars Fogh Iversen, senior vice president, Global Research Technologies, Novo Nordisk. The platform will comprise several highly automated and integrated cells for production, characterisation and functional analysis of thousands of biologic compounds every month. Its scop

Conquest Invests in 5 Greenfield Onshore Wind Parks Totalizing 43MW in the Flanders Region24.1.2020 15:37:00 EETPress release

Conquest, acting through the Conquest Sustainable Infrastructure fund, announced the transaction was closed after an exclusive agreement had been reached with ENGIE Electrabel. Conquest acquires 51% of a portfolio expected to provide 111 GWh per annum of renewable power representing the annual electricity consumption of about 32,000 Belgian homes from early 2021 onwards. The projects benefit from 15 to 20-year green certificates local remuneration schemes, and thus generate yearly secured revenues. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200124005221/en/ Credit: Electrabel While the energy and digital transitions continue to drive the infrastructure sector, Conquest keeps building its diversified sustainable real asset portfolio in Western European markets. The success lies in years of collaboration and long-lasting partnerships with fellow industry experts who can notably facilitate access to new growth opportunities

Fluence Expands EMEA Footprint with Horticulture Partners in Papenburg, Germany24.1.2020 14:00:00 EETPress release

Fluence by OSRAM (Fluence), a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and agriculture production, announced today it is expanding its presence in the Emsland region of Germany through partnerships with growers and other horticulture specialists operating out of Papenburg. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200124005109/en/ Friedrich Schulz’s 5.5 hectare farm—which grows herbs year-round in addition to lettuce, peppers and chives—utilizing VYPR 2p fixtures. (Photo: Business Wire) Given Papenburg’s decades-long history of attracting horticulture experts, Fluence’s innovative lighting solutions for horticulture are a natural fit for the region’s tomato, cucumber, leafy greens and herb growers. Forging connections with Papenburg’s horticultural leaders Elektro Evers, an engineering firm specializing in greenhouse technology, is Fluence’s exclusive systems integrator

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom